UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348

2019

Volltextzugriff (PDF)

Last observation carry-forward and last observation analysis

Statistics in medicine, 2003-08, Vol.22 (15), p.2429-2441

2003

Volltextzugriff (PDF)

Single-arm phase II three-outcome designs with handling of over-running/under-running

Statistical theory and related fields, 2023-10, Vol.ahead-of-print (ahead-of-print), p.1-11

2023

Volltextzugriff (PDF)

Target toxicity design for phase I dose-finding

Statistical theory and related fields, 2021-04, Vol.5 (2), p.149-161

2021

Volltextzugriff (PDF)

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Clinical cancer research, 2019-08, Vol.25 (16), p.4888-4897

2019

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3401-3408

2015

Volltextzugriff (PDF)

Single-arm phase IIA clinical trials with go/no-go decisions

Contemporary clinical trials, 2012-11, Vol.33 (6), p.1272-1279

Zhong, Bob

2012

Volltextzugriff (PDF)

A theory for testing hypotheses under covariate-adaptive randomization

Biometrika, 2010-06, Vol.97 (2), p.347-360

2010

Volltextzugriff (PDF)

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Targeted oncology, 2015-03, Vol.10 (1), p.111-123

2015

Volltextzugriff (PDF)

One-Sample Proportion Testing Procedures for Hypothesis of Inequality

Journal of biopharmaceutical statistics, 2013-05, Vol.23 (3), p.604-617

2013

Volltextzugriff (PDF)

FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4542-4542

2019

Volltextzugriff (PDF)

Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4543-4543

2019

Volltextzugriff (PDF)

TRLS-03. A PHASE 1/2 STUDY ASSESSING SAFETY AND PHARMACOKINETICS OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR CENTRAL-NERVOUS-SYSTEM TUMORS AND SAFETY AND EFFICACY OF CEMIPLIMAB IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA, NEWLY DIAGNOSED HIGH-GRADE GLIOMA, OR RECURRENT HIGH-GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2024-06, Vol.26 (Suppl 4), p.0-0

2024

Volltextzugriff (PDF)

Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.450-450

2018

Volltextzugriff (PDF)

PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer

Future oncology (London, England), 2021-01, Vol.17 (2), p.137-149

2021

Volltextzugriff (PDF)

Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4074-4074

2017

Volltextzugriff (PDF)

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4503-4503

2018

Volltextzugriff (PDF)

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.411-411

2018

Volltextzugriff (PDF)

A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4575-TPS4575

2016

Volltextzugriff (PDF)

TESTING THE AGREEMENT OF TWO QUANTITATIVE ASSAYS IN INDIVIDUAL MEANS

Communications in statistics. Theory and methods, 2002-07, Vol.31 (8), p.1283-1299

2002

Volltextzugriff (PDF)

Abstract CT080: A phase II study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT080-CT080

2016

Volltextzugriff (PDF)

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia

The Journal of supportive oncology, 2008-01, Vol.6 (1), p.18

2008

Volltextzugriff (PDF)

Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT325-CT325

2014

Volltextzugriff (PDF)

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2501-2501

2014

Volltextzugriff (PDF)

Authors' Reply

Statistics in medicine, 2004-10, Vol.23 (20), p.3242-3244

2004

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Sprache

Englisch
(71)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(22)
Humans
(19)
Physical Sciences
(18)
Technology
(13)
Mathematics
(12)
Statistics & Probability
(12)
Engineering
(8)
Engineering, Electrical & Electronic
(7)
Pharmacology & Pharmacy
(7)
Sample Size
(7)
Statistics
(7)
Adult
(6)
Oncology
(6)
Aged
(5)
Clinical Trials
(5)
Computer Science
(5)
Data Interpretation, Statistical
(5)
Exact Sciences And Technology
(5)
Female
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Last observation carry-forward and last observation analysis

Single-arm phase II three-outcome designs with handling of over-running/under-running

Target toxicity design for phase I dose-finding

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Single-arm phase IIA clinical trials with go/no-go decisions

A theory for testing hypotheses under covariate-adaptive randomization

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

One-Sample Proportion Testing Procedures for Hypothesis of Inequality

FGFR-altered, advanced urothelial carcinoma (UC) and response to chemotherapy prior to receiving erdafitinib

Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC)

Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)

PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer

Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing

A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations

TESTING THE AGREEMENT OF TWO QUANTITATIVE ASSAYS IN INDIVIDUAL MEANS

Abstract CT080: A phase II study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia

Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors

Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors

Authors' Reply

Suchergebnisse filtern